Exact Sciences has completed a secondary stock offering, selling 11.5 million shares of common stock.
The transaction, which includes an extra 1.5 million shares sold through the underwriters' option to buy additional stock, will give the Madison company $137.7 million in net proceeds.
The money is expected to be used to work toward Food & Drug Administration approval of Cologuard, Exact Sciences' non-invasive, stool-based, DNA test for colorectal cancer, currently under FDA review.
It will also go for commercializing Cologuard, if approved, and developing additional products.
For further financing deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity